-+ 0.00%
-+ 0.00%
-+ 0.00%

ADMA Biologics 1Q26 adjusted net income rises 22% to $40.7 million; revenue flat at $114.5 million

PUBT·05/06/2026 20:22:23
Listen to the news
ADMA Biologics 1Q26 adjusted net income rises 22% to $40.7 million; revenue flat at $114.5 million
  • ADMA Biologics posted 1Q 2026 net income of USD 45.3 million, up 68% year over year, while revenue was flat at USD 114.5 million.
  • Gross margin widened to 71% from 53% a year earlier, due to a shift toward higher-margin ASCENIV and impact from yield-enhanced manufacturing approved in 2025.
  • ASCENIV revenue rose 28% year over year to USD 97.5 million, while BIVIGAM revenue dropped 54% to USD 15.4 million amid increased competitive dynamics and distributor ordering variability in U.S. plasma-derived therapies and immunoglobulin.
  • Operating cash flow totaled USD 58 million; management said April demand supports a 2Q run rate in line with 1Q direct sales, with early signs of normalization in ordering patterns.
  • ADMA forecast FY 2026 revenue of USD 530 million to USD 560 million, while withdrawing long-term guidance to reflect evolving U.S. plasma products and IG market competitive dynamics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061605PRIMZONEFULLFEED9714725) on May 06, 2026, and is solely responsible for the information contained therein.